Wat is de prijs voor AP Biosciences Inc (6945)

Het prijs van AP Biosciences Inc (6945) is $3.08

Wat is de marktkapitalisatie voor AP Biosciences Inc (6945)

Marktkapitalisatie voorAP Biosciences Inc (6945) is $299.18M

AP Biosciences Inc (6945) Winst

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.

Jaar	Winst	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Winst

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Winst	Winstverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

Winst

Winstverschil

Land